Decreasing proinsulin degradation in pancreatic β-cells therefore potentially opens new avenues for treatment of type 1 diabetes, as blocking proinsulin degradation may affect the presentation of proinsulin-derived epitopes via MHC class I molecules to CD8+ T-cells [45]. This evidence concerns the gene INS and type 1 diabetes mellitus.